n/a
Article Publish Status: FREE
Abstract Title:

Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer.

Abstract Source:

Front Pharmacol. 2020 ;11:586885. Epub 2020 Nov 12. PMID: 33343354

Abstract Author(s):

Jia-Rong Huang, Sheng-Te Wang, Meng-Ning Wei, Kun Liu, Jing-Wen Fu, Zi-Hao Xing, Zhi Shi

Article Affiliation:

Jia-Rong Huang

Abstract:

Colorectal cancer is one of the most common and lethal cancers in the world. An important causative factor of colorectal cancer is ulcerative colitis. In this study, we investigated the therapeutic effects of piperlongumine (PL) on the dextran sulfate sodium (DSS)-induced acute colitis and azoxymethane (AOM)/DSS-induced colorectal cancer mouse models. Our results showed that PL could inhibit the inflammation of DSS-induced mouse colitis and reduce the number of large neoplasms (diameter>2 mm) of AOM/DSS-induced mouse colorectal cancer by downregulation of proinflammatory cytokines cyclooxygenase-2 and interleukin-6 and epithelial-mesenchymal transition-related factors, β-catenin, and snail expressions, but fail to improve the colitis symptoms and to decrease the incidence of colonic neoplasms and the number of small neoplasms (diameter<2 mm). These data suggested that PL might be an effective agent in treating colitis and colorectal cancer.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.